Fimasartan
Trials 42 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 18 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07421414 Comparator | Apr → Jun 2026 overdue | essential hypertension | Boryung Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT01671020 Comparator | Jun → Jul 2012 | — | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01146938 Comparator | May 2010 → Feb 2011 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01007409 Comparator | Oct → Nov 2009 | — | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00938197 Comparator | Jun → Aug 2009 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00923533 Comparator | Mar → May 2009 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00937534 Comparator | Jan → Aug 2009 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00923611 Comparator | Sep 2007 → Jun 2008 | hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00937651 Comparator | Apr 2005 → Jun 2006 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT03156842 Comparator | May 2017 → Dec 2018 | essential hypertension, hyperlipidemia | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02166814 Comparator | Aug 2014 → Sep 2015 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02152306 Comparator | Apr 2014 → Mar 2015 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01258673 Comparator | Nov 2010 → Dec 2011 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01135212 Comparator | Apr 2010 → Apr 2011 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00922480 Comparator | Dec 2008 → Jul 2009 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT04061824 Comparator | May 2016 → Dec 2018 | hyperlipidemia, hypertensive disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01691118 Comparator | Sep 2012 → Aug 2015 | hypertensive disorder | Asan Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01589380 Comparator | Apr 2012 → May 2013 | aortic valve stenosis | Seoul National University Hospital | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 67 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fimasartan | “One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin,...” NCT04061824 ↗59“Fimasartan is the ninth angiotensin receptor blocker to be developed.” PMID 29284530 ↗ Dec 2017 “Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide” NCT03629067 ↗ “fimasartan(60mg,QD)+Vytorin(10mg,QD)” NCT02378064 ↗ “Fimasartan 30 mg/Indapamide 1.5 mg” NCT07421414 ↗ “BR1015-1(Fimasartan 60mg)” NCT05097794 ↗ |
| Known as | BR-A-657 | “Fimasartan (BR-A-657; BR-A-657-K; Kanarb®), an angiotensin II receptor antagonist with selectivity for the AT(1) receptor subtype, is being developed by Boryung Pharmaceutical...” PMID 21740078 ↗ Aug 20112“Fimasartan (BR-A-657) is a novel, non-peptide angiotensin II receptor antagonist with a selective type I receptor blockade effect.” PMID 21910510 ↗ Oct 2011 “AIM: Fimasartan (BR-A-657) is a new angiotensin II receptor antagonist used as antihypertensive agent.” PMID 21394036 ↗ Jun 2011 |
| Known as | BR-A-657-K | “Fimasartan (BR-A-657; BR-A-657-K; Kanarb®), an angiotensin II receptor antagonist with selectivity for the AT(1) receptor subtype, is being developed by Boryung Pharmaceutical...” PMID 21740078 ↗ Aug 20116“Study to Compare and Assess the Safety and Pharmacokinetic Characteristics After Oral Administration of Fimasartan (BR-A-657∙K) in Healthy Elderly and Young Male Volunteers” NCT00937534 ↗ “Fimasartan (BR-A-657•K), a selective blocker of AT1 receptor subtype, showed the rapid and potent antihypertensive effect in many hypertensive models.” NCT00922480 ↗ “Fimasartan (BR-A-657•K), a selective blocker of AT1 receptor subtype, showed the rapid and potent antihypertensive effect in many hypertensive models.” NCT00937651 ↗ “Fimasartan (BR-A-657-K), a selective blocker of AT1 receptor subtype” NCT00923611 ↗ “Fimasartan (BR-A-657-K), a selective blocker of AT1 receptor subtype” NCT00923533 ↗ “Fimasartan(BR-A-657∙K) 30mg Compared to Placebo” NCT01672476 ↗ |
| Known as | Fimasartan (BR-A-657; CAS : 247257-48-3; Kanarb) | “Fimasartan (BR-A-657; CAS : 247257-48-3; Kanarb)” NCT01589380 ↗ |
| Known as | FMS | “This study evaluated the efficacy and safety of fimasartan (FMS) and indapamide (IND) sustained release (SR) combination therapy.” PMID 42163997 ↗ May 20263“Fimasartan (FMS) is an AT1 receptor antagonist indicated for once a day administration” NCT02466490 ↗ “fimasartan 60 mg/amlodipine 10 mg + rosuvastatin 20 mg (FMS/ALD + RSV) as study group” PMID 36451242 ↗ Dec 2022 “fimasartan 120 mg (FMS) alone 3)” PMID 28057081 ↗ Jan 2017 |
| Known as | Kanarb | “Fimasartan (BR-A-657; BR-A-657-K; Kanarb®), an angiotensin II receptor antagonist with selectivity for the AT(1) receptor subtype, is being developed by Boryung Pharmaceutical...” PMID 21740078 ↗ Aug 20111“evaluate the absolute bioavailability of Kanarb® tablet (fimasartan)” NCT01671020 ↗ |
| Action | Inhibit | “Fimasartan, a selective angiotensin II type 1 receptor blocker, was approved in Korea for the treatment of patients with mild to moderate hypertension.” PMID 23932463 ↗ Aug 2013 |
| Modality | Small molecule | “Fimasartan (BR-A-657) is a novel, non-peptide angiotensin II receptor antagonist with a selective type I receptor blockade effect.” PMID 21910510 ↗ Oct 2011 |
| Route | Oral | “Korean patients with mild to moderate essential hypertension were enrolled and randomly received once-daily oral fimasartan 60 or 120 mg or valsartan 80 mg for 8 weeks.” PMID 23932463 ↗ Aug 2013 |